drugset / Trial / NCT06328608

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

NCT06328608

Phase 2/3 Recruiting 22 enrolled Chiesi Farmaceutici S.p.A. ICON plc · collab
NaSingle-groupOpen-labelTreatment

Summary

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.

Timeline

Start
2025-07-29
Primary completion
2028-10
Completion
2031-04

Drugs

EvaluationDrugModalityDoseRoute
Subject pegunigalsidase alfa Protein / enzyme biologic 1 mg/kg Intravenous

Indications